We recently compiled a list of the 12 Best Performing Healthcare Stocks to Buy Right Now. Insmed Incorporated is one of them.
Insmed Incorporated (NASDAQ:INSM) tops our list for being one of the best performing stocks. It is a biopharmaceutical company focused on rare diseases, with a portfolio targeting serious conditions with unmet medical needs. Its flagship product, ARIKAYCE® (amikacin liposome inhalation suspension), addresses lung infections and has shown strong market growth.
Recently, INSM gained significant investor attention after FDA approval of Brinsupri for non-CF bronchiectasis. This milestone boosted stock performance, with shares rising nearly 9%, and prompted analysts to raise price targets, JPMorgan to $135, Stifel to $145, and H.C. Wainwright to $240, reflecting Brinsupri’s potential to generate $7 billion in revenue by 2033.
Financially, the business reported Q2 2025 revenues of $107.4 million for ARIKAYCE, up 19% year-over-year, with a strong gross margin of 75.7%, despite a net loss of $321.7 million. The company also completed a public offering, raising approximately $823 million to fund pipeline development and commercialization.
Looking ahead, Insmed Incorporated’s pipeline includes several promising late-stage assets. Brensocatib received FDA approval on August 12, 2025, while the Treprostinil Palmitil Inhalation Powder (TPIP) program is progressing toward Phase 3 studies for pulmonary hypertension, expected to begin in late 2025 and early 2026. These developments position INSM for continued growth and expansion in the rare disease market.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW
